团队人员

1.   研究组长：侯陵研究员，博士，研究员，博士生导师。曾师从发育生物学教授刘筠院士并获硕士学位。留学日本Tohoku大学并获博士学位，后赴美国印第安纳大学医学院从事博士后，并先后在美国国立卫生研究院(NIH)任助理研究员，副研究员，Scientist。2008年作为海外高层次人才引进温州医科大学，任眼视光学与视觉科学国家重点实验室研究员，浙江省模式生物技术与应用重点实验室副主任。现为国家重点研发计划评审专家、国家自然科学基金重大研究计划和面上项目评议专家，浙江省自然基金委评审专家、中国遗传咨询网专家委员会成员, PLOS One的编委，The American Journal of Human Genetics, Stem Cells, Journal of Investigative Dermatology, Pigment Cell & Melanoma Research, Journal of Dermatological Science, Journal of Photochemistry & Photobiology, Experimental Dermatology, Mechanisms of Development, PLOS One, Journal of Cellular and Molecular Medicine, Differentiation等学术期刊评委。

2.   工作人员：陈瑜、麻晓银、苏中渊、李辉荣、王靓

研究方向

视网膜色素上皮细胞生物学与视网膜退行性病变

视网膜退行性病变是世界范围内主要的致盲性眼病，目前尚无有效的治疗方法，其重要原因之一是该类疾病的发生发展的分子机制尚未完全阐明。本团队的研究兴趣之一是视网膜发育及功能障碍中的转录调控及信号通路。我们通过利用先天性视网膜变性，年龄相关视网膜病变及氧化应激诱导的视网膜变性小鼠模型，结合细胞生物学技术、分子生物学技术，Chip-seq，RNA-seq高通量筛选等技术，以阐明特异性视网膜变性的分子和细胞机理。在此基础上，我们将对小鼠采用基因疗法或药物治疗，以期望找到可有效减慢或延缓视网膜退行性病变的有效治疗方式。

Laboratory of Developmental Cell Biology and Disease

Team Members

1.    Principal investigator: Ling Hou, MD, PhD

Dr. Ling Hou received his Ph.D. in 1992 from Tohoku University, Japan, where he worked with Takuji Takeuchi. From 1992 to 1996, he did postdoctoral training at the Indiana University School of Medicine, USA. From 1997 to 2000, he worked as a Research Associate Scientist with Heinz Arnheiter at NIH, USA. From 2000 to 2007, he was a Senior Research Fellow and then a Staff Scientist at NHGRI, NIH in USA. Now he works as a Senior Investigator of Cell Biology, and Molecular Genetic and Developmental Genetic Ophthalmology at State Key Laboratory of Ophthalmology, Optometry and Vision Science in China, where his program continually investigates the molecular and cellular mechanisms underlying RPE cell & melanocyte biology and retinal degeneration.

2.   Team Staff：Yu Chen，Xiaoyin Ma, Zhongyuan Su，Huirong Li，Jing Wang

Scope of Research Proposal

Retinal Pigment Epithelial Cell Biology and Retinal Degeneration

Retinal degeneration is the leading cause of blindness in the world, which still lacks effective treatments. One of the reasons is the molecular mechanisms of the retinal degeneration have not been fully understood. Our research interest is the transcriptional regulation and signaling pathways in retinal development and dysfunctions. We use the congenital retinal degeneration, age-related retinal degeneration, and stress induced retinal generation mice models, combined with cellular biology, molecular biology and high throughput assays, such as ChIP-seq, RNA-seq to elucidate the molecular and cellular mechanisms of the specific retinal degeneration. Based on the elucidated mechanisms, we will use the gene therapy or drug treatment to treat the mice, we hope we can find effective ways to delay or slow down the retinal degeneration.